Who are mesalamine granules's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Colazal, Rowasa, MESALAMINE, Azulfidine En-Tabs, Tofacitinib plus mesalamine, Azulfidine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mesalamine-granules.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

mesalamine granules — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

mesalamine granules (mesalamine granules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: aminosalicylate. Area: Gastroenterology.

phase 3 aminosalicylate Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

mesalamine granules (mesalamine granules) — Dr. Falk Pharma GmbH. Mesalamine works by releasing aminosalicylates in the colon to reduce inflammation and prevent symptoms of ulcerative colitis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
mesalamine granules TARGET	mesalamine granules	Dr. Falk Pharma GmbH	phase 3	aminosalicylate
Colazal	BALSALAZIDE	Valeant Pharms Intl	marketed	Aminosalicylate	Prostaglandin G/H synthase 1	2000-01-01
Rowasa	Mesalazine	Meda Pharms	marketed	Aminosalicylate [EPC]	Prostaglandin G/H synthase 2	1987-01-01
MESALAMINE	MESALAMINE		marketed	Aminosalicylate [EPC]	Cyclooxygenase	1987-01-01
Azulfidine En-Tabs	SULFASALAZINE	Pfizer	marketed	Aminosalicylate [EPC]	Flavin reductase (NADPH)	1950-01-01
Tofacitinib plus mesalamine	Tofacitinib plus mesalamine	Post Graduate Institute of Medical Education and Research, Chandigarh	marketed	JAK inhibitor plus aminosalicylate	JAK1/JAK3 (tofacitinib); unclear specific target for mesalamine (likely prostaglandin-related)
Azulfidine	Sulfasalazine	Pfizer Inc.	marketed	Sulfonamide; aminosalicylate	5-aminosalicylic acid (5-ASA) moiety; connective tissue affinity

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-07-24 — Rowasa · 7645801 · US
2027-07-24 — MESALAMINE · 7645801 · Compound · US
2028-06-06 — Rowasa · 8217083 · US
2028-06-06 — MESALAMINE · 8436051 · Formulation · US
2028-06-06 — Rowasa · 8436051 · US
2028-06-06 — MESALAMINE · 8217083 · Formulation · US
2030-05-01 — Rowasa · 8865688 · US
2030-05-01 — MESALAMINE · 8865688 · Method of Use · US

Sponsor landscape (aminosalicylate class)

Dr. Falk Pharma GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). mesalamine granules — Competitive Intelligence Brief. https://druglandscape.com/ci/mesalamine-granules. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing